Literature DB >> 15751604

Immunophenotypic characterisation of peripheral blood lymphocytes in autoimmune polyglandular syndrome type 1: clinical study and review of the literature.

Roberto Perniola1, Giambattista Lobreglio, Maria Cristina Rosatelli, Elena Pitotti, Elisa Accogli, Corrado De Rinaldis.   

Abstract

Autoimmune endocrinopathies are characterised by an increased number of peripheral blood lymphocytes (PBL) expressing activation/ memory markers on their surface. The aim of this study was to determine whether a similar finding could be detected in a group of 11 paediatric and young adult patients suffering from autoimmune polyglandular syndrome type 1 (APS1), also called autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), as very few data have previously been reported in this field. The control group was made up of 11 sex- and age-matched healthy subjects. Fifteen lymphocyte subsets were compared, in terms of percentage and absolute number, and statistical analysis was performed by the Mann-Whitney test. Measurement of T (CD3+), B (CD19+), natural killer (NK, CD3-CD16/56+), CD4+ and CD8+ T lymphocytes showed that patients with APS1 had a higher percentage and absolute count of T lymphocytes: this was entirely due to the statistically larger CD3+CD4+ fraction. Patients with APS1 also had slightly fewer B and NK lymphocytes, but the difference was negligible. Comparison of CD4+ subpopulations bearing activation and naive/memory antigens (marked by CD69, CD25, anti-HLA-DR, CD45RA and CD45RO) showed that patients with APS1 had generally larger percentages and absolute counts of these subsets: however, only the percentage and absolute size of the CD4+CD25+ subset (p = 0.0354 and p = 0.0151, respectively), and the absolute number of the CD4+ anti-HLA-DR+ and CD4+ CD45RO+ subsets (p = 0.0193 and p = 0.0209, respectively) were significantly higher. Interestingly, patients with APS1 also had significantly fewer CD8+CD11b+ and CD3-CD8+ cells. In conclusion, PBL distribution in APS1 resembles that of other autoimmune diseases. Further studies are needed to confirm and possibly extend these data.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15751604     DOI: 10.1515/jpem.2005.18.2.155

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  8 in total

1.  Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Elise M N Ferre; Stacey R Rose; Sergio D Rosenzweig; Peter D Burbelo; Kimberly R Romito; Julie E Niemela; Lindsey B Rosen; Timothy J Break; Wenjuan Gu; Sally Hunsberger; Sarah K Browne; Amy P Hsu; Shakuntala Rampertaap; Muthulekha Swamydas; Amanda L Collar; Heidi H Kong; Chyi-Chia Richard Lee; David Chascsa; Thomas Simcox; Angela Pham; Anamaria Bondici; Mukil Natarajan; Joseph Monsale; David E Kleiner; Martha Quezado; Ilias Alevizos; Niki M Moutsopoulos; Lynne Yockey; Cathleen Frein; Ariane Soldatos; Katherine R Calvo; Jennifer Adjemian; Morgan N Similuk; David M Lang; Kelly D Stone; Gulbu Uzel; Jeffrey B Kopp; Rachel J Bishop; Steven M Holland; Kenneth N Olivier; Thomas A Fleisher; Theo Heller; Karen K Winer; Michail S Lionakis
Journal:  JCI Insight       Date:  2016-08-18

Review 2.  Autoimmune polyendocrine syndrome type 1 (APECED) in the Indian population: case report and review of a series of 45 patients.

Authors:  A Fierabracci; A Arena; F Toto; N Gallo; A Puel; M Migaud; M Kumar; K G Chengappa; R Gulati; V S Negi; C Betterle
Journal:  J Endocrinol Invest       Date:  2020-08-07       Impact factor: 4.256

3.  Expanded CD4(+) Effector/Memory T Cell Subset in APECED Produces Predominantly Interferon Gamma.

Authors:  Nelli Heikkilä; Sini M Laakso; Helga Mannerström; Eliisa Kekäläinen; Päivi Saavalainen; Hanna Jarva; Tommi P Arstila
Journal:  J Clin Immunol       Date:  2016-06-04       Impact factor: 8.317

Review 4.  Autoimmune Addison's Disease as Part of the Autoimmune Polyglandular Syndrome Type 1: Historical Overview and Current Evidence.

Authors:  Roberto Perniola; Alessandra Fierabracci; Alberto Falorni
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

5.  Impact of methimazole treatment on magnesium concentration and lymphocytes activation in adolescents with Graves' disease.

Authors:  Maria Klatka; Ewelina Grywalska; Malgorzata Partyka; Malgorzata Charytanowicz; Jacek Rolinski
Journal:  Biol Trace Elem Res       Date:  2013-05-11       Impact factor: 3.738

Review 6.  Human APECED; a Sick Thymus Syndrome?

Authors:  T Petteri Arstila; Hanna Jarva
Journal:  Front Immunol       Date:  2013-10-07       Impact factor: 7.561

Review 7.  Immunodeficiency in DiGeorge Syndrome and Options for Treating Cases with Complete Athymia.

Authors:  E Graham Davies
Journal:  Front Immunol       Date:  2013-10-31       Impact factor: 7.561

Review 8.  Type 1 Diabetes in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Syndrome (APECED): A "Rare" Manifestation in a "Rare" Disease.

Authors:  Alessandra Fierabracci
Journal:  Int J Mol Sci       Date:  2016-07-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.